Tests AZD1163 in adults with moderately to severely active rheumatoid arthritis
Tests the drug AZD1163 against a placebo in adults with active rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Key facts
- Where
- Aurora, Austin, Baltimore, Baytown, Boynton Beach, Glendale, Henderson, Houston, Jacksonville, Kansas City, La Jolla, Lake Charles, Marietta, Mesquite, Myrtle Beach, New Bedford, Prescott Valley, Rockville, San Dimas, San Leandro, Skokie, South Miami, St Louis, Tampa, Tomball, Tucson, Willowbrook, and Winter Haven, United StatesSee the 28 sites
- Phase
- Phase 2
Where in United States
- AuroraAurora, United StatesTaking people
- AustinAustin, United StatesTaking people
- BaltimoreBaltimore, United StatesTaking people
- BaytownBaytown, United StatesTaking people
- Boynton BeachBoynton Beach, United StatesNo longer taking part
- GlendaleGlendale, United StatesTaking people
- HendersonHenderson, United StatesTaking people
- HoustonHouston, United StatesTaking people
- JacksonvilleJacksonville, United StatesNo longer taking part
- Kansas CityKansas City, United StatesTaking people
- La JollaLa Jolla, United StatesTaking people
- Lake CharlesLake Charles, United StatesTaking people
- MariettaMarietta, United StatesTaking people
- MesquiteMesquite, United StatesTaking people
- Myrtle BeachMyrtle Beach, United StatesTaking people
- New BedfordNew Bedford, United StatesTaking people
- Prescott ValleyPrescott Valley, United StatesNo longer taking part
- RockvilleRockville, United StatesNot yet recruiting
- San DimasSan Dimas, United StatesNo longer taking part
- San LeandroSan Leandro, United StatesTaking people
- SkokieSkokie, United StatesTaking people
- South MiamiSouth Miami, United StatesNo longer taking part
- St LouisSt Louis, United StatesTaking people
- TampaTampa, United StatesNo longer taking part
- TomballTomball, United StatesTaking people
- TucsonTucson, United StatesTaking people
- WillowbrookWillowbrook, United StatesTaking people
- Winter HavenWinter Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07276581
- Record updated
- 9 October 2026
- Original description
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.Read full original descriptionShow less
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Inclusion; Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening; Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal; Have a positive ACPA at screening; A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi; A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation; Exclusion; History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible; Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.